You are here: Industry Insights > BluePrint

News List

Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology b3cnewswire
June 21, 2019
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology.
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST drugs
June 17, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST.
New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients with Poor Response to Anti-Estrogen Therapy Who May b3cnewswire
April 25, 2019
New Data Show BluePrint® Identifies Estrogen Receptor Positive Breast Cancer Patients with Poor Response to Anti-Estrogen Therapy Who May Benefit from Neoadjuvant Chemotherapy.
Third Akorn sterile drug plant hit by FDA as new CEO lays out blueprint for a better future fiercepharma
March 03, 2019
Akorn Pharmaceuticals, which had a $4.3 billion buyout by Fresenius tank last fall, just can’t seem to catch a break.
Blueprint eyes quick filing for GIST drug avapritinib pharmaphorum
December 13, 2018
Blueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set it on course for regulatory filings – and a close race to market with rival Deciphera.
Blueprint Announces Updated Results from Ongoing Avapritinib Trial americanpharmaceuticalreview
December 04, 2018
Blueprint Medicines announced updated results for the Phase 1 EXPLORER clinical trial of avapritinib, a potent and highly selective inhibitor of D816V mutant KIT.....

Previous page 1 2 Next page